B+
Bull case
20%
Probability
Target price
$19.00
+21.1% vs current
VTRS
ViatrisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$15.80
+0.7% vs current
B-
Bear case
25%
Probability
Target price
$12.50
-20.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-28
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.3
Score
AI commentary
Post-Q1 coverage was constructive but not exuberant: the company and Reuters both pointed to a beat and reaffirmed guidance, and the stock reacted positively around the print, but the packet does not show a strong post-earnings analyst revision wave. With the FDA decision on meloxicam still months away and no social context available, this remains a monitor-oriented setup rather than a high-conviction re-rate.
RankAlpha Sentiment Codex - 2026-05-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 2026 beat and guidance reaffirmationMedium impact
The May 7 Q1 package pointed to a stronger-than-expected first quarter, reaffirmed 2026 guidance, and highlighted Greater China strength, branded-drug demand, launch execution, and more than $2.5B of expected cash available for deployment in 2026. Reuters also reported the revenue/EPS beat and a positive immediate market reaction. [#10-Q-2026-05-07] [#PR-2026-05-07]
2026-12-27eventFast-acting meloxicam now has a Dec. 27, 2026 FDA clockMedium impact
Viatris said the FDA accepted the NDA for fast-acting meloxicam and assigned a PDUFA goal date of Dec. 27, 2026, creating a clear binary regulatory milestone for a value-added pipeline asset. [#PR-2026-05-18]
2026-12-31catalystJapan launch execution and capital-deployment capacity remain supportiveMedium impact
The Q1 release flagged additional product-launch progress, including Effexor in Japan, and reiterated that Viatris expects substantial 2026 cash generation for deployment, which gives the story a durable but modest operating tailwind beyond the core generics base. [#PR-2026-05-07] [#PR-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-28 • Updated nightlySource: Internal modelMethodology